What are the surgical indications for mitral valve repair or replacement?

Surgical Indications for Mitral Valve Replacement/Repair

Surgery is indicated for all symptomatic patients with severe primary mitral regurgitation regardless of left ventricular ejection fraction, and for asymptomatic patients when LVEF ≤60% or LVESD ≥40 mm, with mitral valve repair strongly preferred over replacement when anatomically feasible. 1

Primary (Degenerative) Mitral Regurgitation

Symptomatic Patients

• Surgery is mandatory for all symptomatic patients with severe primary MR and LVEF >30% (Class I recommendation) 1
• Even patients with LVEF between 30-60% or LVESD <55 mm should undergo surgery when symptomatic 1
• For symptomatic patients with LVEF <30%, surgery may be considered if refractory to medical therapy, high likelihood of durable repair exists, and comorbidity burden is low 1

Asymptomatic Patients with LV Dysfunction

• Surgery is indicated when LVEF ≤60% and/or LVESD ≥40 mm (Class I recommendation) 1
• This represents a critical threshold—do not wait for symptoms to develop once these parameters are met, as outcomes worsen with delay 1
• LVESD ≥40 mm is an independent surgical indication even when LVEF appears preserved 1

Asymptomatic Patients with Preserved LV Function

• New-onset atrial fibrillation secondary to MR mandates surgery (Class I) 1
• Pulmonary hypertension with systolic pulmonary artery pressure ≥50 mmHg requires surgery (Class I) 1
• Surgery should be considered when probability of durable repair exceeds 95%, expected operative mortality is <1%, and the procedure is performed at a high-volume valve center (Class IIa) 1
• Significant left atrial dilatation (LA volume index ≥60 mL/m² or diameter >55 mm) may justify surgery if durable repair is likely (Class IIa) 1
• Progressive LV remodeling (increase in LV size or decline in EF on ≥3 consecutive imaging studies) triggers consideration for surgery (Class IIa) 1

Concomitant Cardiac Surgery

• Concomitant mitral valve surgery is mandatory for patients with severe primary MR undergoing any other cardiac operation (Class I) 1
• When severe MR coexists with need for CABG, adding mitral valve surgery is reasonable (Class IIa) 1
• Some guidelines endorse mitral valve surgery even for moderate MR when performed together with CABG (Class IIa) 1

Secondary (Functional) Mitral Regurgitation

Medical Optimization First

• Guideline-directed medical therapy (GDMT) must be maximized before considering any intervention 2
• GDMT includes ACE inhibitors or ARBs as first-line therapy, beta-blockers to prevent LV deterioration, mineralocorticoid receptor antagonists, diuretics for fluid overload, and nitrates for acute dyspnea 2
• Cardiac resynchronization therapy (CRT) should be implemented in patients meeting criteria (typically LVEF ≤35%, QRS ≥150 ms, LBBB) before valve intervention 2

Surgical Indications

• Valve surgery may be considered in symptomatic patients with severe secondary MR despite optimal GDMT (Class IIa) 1
• MV surgery is recommended for patients with severe secondary MR undergoing CABG and LVEF >30% (Class I) 1
• For secondary MR, repair with undersized rigid annuloplasty ring is preferred in selected patients without advanced LV remodeling 1

Transcatheter Edge-to-Edge Repair (TEER)

• TEER should be considered for patients with severe secondary MR, LVEF 20-50%, persistent NYHA class II-IV symptoms despite optimal medical therapy and CRT when indicated 2
• TEER is reasonable for prohibitive surgical risk patients with favorable anatomy: LVEF 20-50%, LVESD ≤70 mm, and pulmonary artery systolic pressure ≤70 mmHg (Class IIa) 1

Repair vs. Replacement Decision Algorithm

Strong Preference for Repair

• Mitral valve repair is strongly preferred over replacement when anatomically feasible, as it provides superior outcomes 2
• For primary MR, repair is specifically recommended over replacement for posterior-leaflet disease (Class I) and for anterior-leaflet or bileaflet involvement when feasible (Class I) 1
• Repair provides greater regression of left heart dimensions, normalization of left ventricular function, and superior long-term survival 3

Patient-Specific Considerations for Repair vs. Replacement

• Patients younger than 65 years with ischemic etiology of functional MR, poor ejection fraction (<30%), severe LV dilatation (LVEDD >60 mm), and presence of atrial fibrillation have significantly higher mortality rates after MV replacement compared to repair (HR 3.0) 4
• Patients between 65-75 years have higher risk of death with mitral valve replacement (HR 1.7) 4
• In patients older than 75 years, the surgical approach (repair or replacement) has no effect on postoperative survival 4
• The most severely ill patients with secondary MR and those with severe bileaflet tethering should be treated with bioprosthetic mitral valve replacement rather than repair 5

Center Requirements

• Surgery should be performed at high-volume centers with documented high repair rates (>90% for isolated posterior leaflet prolapse) and operative mortality <1% 2
• Not referring patients to experienced mitral valve centers where repair rates are high is a critical pitfall to avoid 1

Special Circumstances

Acute Severe MR

• Urgent surgery is indicated in patients with acute severe MR 1

Moderate MR

• Surgery is NOT indicated for isolated moderate primary MR in asymptomatic patients, even with excellent valve repair feasibility 6
• Multidisciplinary heart team evaluation is warranted to assess whether intervention is appropriate for symptomatic patients with moderate primary MR 6
• MV repair may be considered at the time of CABG for patients with multivessel coronary artery disease and moderate secondary MR 6

Surveillance Requirements

Severe MR (Asymptomatic)

• Clinical and echocardiographic follow-up every 6-12 months 2, 1
• Serial BNP measurement may aid timing of intervention (Class IIb) 1
• Exercise echocardiography, ambulatory Holter monitoring, and cardiac magnetic resonance imaging can be useful for risk stratification (Class IIb) 1

Moderate MR

• Yearly clinical assessment with echocardiography every 1-2 years 1
• More frequent imaging (every 6 months) if LV dilation is observed 1

Mild MR

• Clinical evaluation every 3-5 years 2, 1

Critical Pitfalls to Avoid

• Do not postpone referral to experienced mitral valve centers (repair rates ≥80-90%, operative mortality <1%) because outcomes are markedly better 1
• Do not wait for symptom development in asymptomatic patients with LV dysfunction (LVEF ≤60% or LVESD ≥40 mm); surgery is indicated 1
• Avoid vasodilator therapy in patients with mitral valve prolapse or hypertrophic cardiomyopathy, as it may exacerbate MR (Class III) 1
• Recognize that LVESD ≥40 mm is an independent surgical indication even when LVEF is preserved 1
• All intervention decisions must involve multidisciplinary heart team discussion, including assessment of valve morphology, MR etiology, patient comorbidities, and surgical risk 2